BALTIMORE, MD--(Marketwired - May 23, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, believes that a slew of recent activity which has occurred in the nanomedicine, or nanobiotechnology industry, bodes well for Nuvilex Inc. (
According to a recent Reuters article, nanomedicine is defined as: "The ability to encapsulate potent drugs in tiny particles measuring billionths of a meter in diameter is opening up new options for super-accurate drug delivery, increasing precision hits at the site of disease with, hopefully, fewer side effects."
It sounds very much like the definition for Nuvilex's Cell-in-a-Box technology.
In the past two months alone, privately held nanobiotechnology leader Bind Therapeutics has closed 3 development deals with drug giants Pfizer, Amgen, and AstraZeneca. Significant upfront dollars have been paid and if all of the proposed drugs under development were to receive approval, it could be worth at least several hundred million dollars to Bind Therapeutics.
It is apparent that the methodology behind the delivery methods of both firms are remarkably similar, as is the primary targeted disease: cancer. In both cases, pro-drugs are encapsulated and targeted directly at the tumor with greater efficacy than traditional methods and with far less toxicity.
Clearly, a great deal of attention and value is beginning to occur for firms developing tiny, targeted delivery systems to treat major diseases like cancer. As Nuvilex edges closer to developing protocols for future trials, industry observers may begin to mention the Company in the same breath as the leading nanobiotechnology firms.
A copy of this article as well as other articles and Nuvilex reports can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com .
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com .
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com .
About Nuvilex, Inc. (
Goldman Small Cap Research Rob Goldman, Analyst 410-609-7100 rob@goldmanresearch.com
